drugset / Trial / NCT05387083
A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
RandomizedParallel-groupQuadruple-blindOther
Summary
This is a Phase 2a, randomized, double-blind, proof-of-concept, single-center study evaluating the safety, tolerability, and whole blood concentration of TP-05 (lotilaner) in the killing of ticks after they have attached to human skin.
Timeline
- Start
- 2022-12-12
- Primary completion
- 2024-06-26
- Completion
- 2024-06-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TP05 | Unknown | — | Oral |
Indications
No indication recorded.